Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review
Journal of Cardiology & Cardiovascular Surgery · 2023
DOI: 10.51271/jccvs-0003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiology & Cardiovascular Surgery, 2023. Verfasst von Mehmet Emin Demir und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Sodium-glucose co-transporter-2 inhibitors are novel antihyperglycemic agents which have crucial effects on the heart and kidneys beyond their glucose-lowering features. Their main clinical benefits have been reported in individuals with type 2 diabetes mellitus, chronic kidney disease, heart failure, and proteinuria. However, adverse reactions (euglycemic ketoacidosis, kidney dysfunction, genital and urinary tract infections, hypovolemia, etc) remain to be the main object of the debate regarding their use. The recruited data have encouraged clinicians to use those medicines in individuals who fit the indications for use.
Zitieren
APA
Demir, M. E., Ercan, Z., & Erdoğan, B. (2023). Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review. Journal of Cardiology & Cardiovascular Surgery. https://doi.org/10.51271/jccvs-0003
Vancouver
Demir ME, Ercan Z, Erdoğan B. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review. Journal of Cardiology & Cardiovascular Surgery. 2023. doi:10.51271/jccvs-0003
BibTeX
@article{Demir2023,
author = {Demir, Mehmet Emin and Ercan, Zafer and Erdoğan, Bülent},
title = {Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review},
journal = {Journal of Cardiology & Cardiovascular Surgery},
year = {2023},
doi = {10.51271/jccvs-0003}
}
EUVIMED